Genetic association studies in osteonecrosis of the femoral head: Mini review of the literature

Skeletal Radiology

Volumn 37, Issue 1, 2008, Pages 1-7

  Hadjigeorgiou, Georgios ^a,b   Dardiotis, Efthimios ^a,b   Dardioti, Maria ^a,b   Karantanas, Apostolos ^c   Dimitroulias, Apostolos ^a   Malizos, Konstantinos ^a,b  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE 1; BLOOD CLOTTING FACTOR 5 LEIDEN; BONE MORPHOGENETIC PROTEIN 6; COLLAGEN TYPE 2; CYTOCHROME P450 2E1; FIBRINOGEN RECEPTOR; LIPOCORTIN 2; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE NECROSIS; DRUG MEGADOSE; EXTRACELLULAR MATRIX; FEMUR HEAD NECROSIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HOMOZYGOSITY; HUMAN; PATHOPHYSIOLOGY; PERTHES DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SICKLE CELL ANEMIA;

ANIMALS; FEMUR HEAD NECROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS;

EID: 36348954522     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-007-0395-2     Document Type: Short Survey

References (44)

1. Hadjigeorgiou GM, Karantanas AH, Zibis A, Dardiotis E, Aggelakis K, Papadimitriou A, et al. Increased frequency of white matter lesions in patients with osteonecrosis (WMLeOn) of the femoral head. Eur J Radiol 2004; 50: 278-284.
2. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002; 32: 94-124.
3. Glueck CJ, Glueck HI, Welch M, Freiberg R, Tracy T, Hamer T, et al. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost 1994; 71: 195-198.
4. Nobillot R, Le Parc JM, Benoit J, Paolaggi JB. Idiopathic osteonecrosis of the hip in twins. Ann Rheum Dis 1994; 53: 702.
5. Boss JH, Misselevich I. Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 2003; 40: 345-354.
6. Liu YF, Chen WM, Lin YF, Yang RC, Lin MW, Li LH, et al. Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med 2005; 352: 2294-2301.
7. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
8. Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin Orthop Relat Res 2004; 422: 251-255.
9. Bjorkman A, Svensson PJ, Hillarp A, Burtscher IM, Runow A, Benoni G. Factor V Leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res 2004; 425: 168-172.
10. Bjorkman A, Burtscher IM, Svensson PJ, Hillarp A, Besjakov J, Benoni G. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg 2005; 125: 51-55.
11. Glueck CJ, Fontaine RN, Gruppo R, Stroop D, Sieve-Smith L, Tracy T, et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res 1999; 366: 133-146.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
13. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
14. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res 2001; 386: 19-33.
15. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
16. Zalavras CG, Malizos KN, Dokou E, Vartholomatos G. The 677C - >T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head. Haematologica 2002; 87: 111-112.
17. Koo KH, Lee JS, Lee YJ, Kim KJ, Yoo JJ, Kim HJ. Endothelial nitric oxide synthase gene polymorphisms in patients with nontraumatic femoral head osteonecrosis. J Orthop Res 2006; 24: 1722-1728.
18. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
19. Hadjigeorgiou GM, Malizos K, Dardiotis E, Aggelakis K, Dardioti M, Zibis A, et al. Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. J Orthop Res 2007; 25: 1087-1093.
20. Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, et al. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 2002; 74: 1147-1152.
21. Asano T, Takahashi KA, Fujioka M, Inoue S, Ueshima K, Hirata T, et al. Relationship between postrenal transplant osteonecrosis of the femoral head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects. Transplantation 2004; 77: 220-225.
22. Celik A, Tekis D, Saglam F, Tunali S, Kabakci N, Ozaksoy D, et al. Association of corticosteroids and factor V, prothrombin, and MTHFR gene mutations with avascular osteonecrosis in renal allograft recipients. Transplant Proc 2006; 38: 512-516.
23. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N, et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003; 13: 675-682.
24. Asano T, Takahashi KA, Fujioka M, Inoue S, Satomi Y, Nishino H, et al. Genetic analysis of steroid-induced osteonecrosis of the femoral head. J Orthop Sci 2003; 8: 329-333.
25. Kechli AM, Wilimas JA, Pui CH, Park VM, Tonkel S, Deitcher SR. Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy. J Pediatr 1999; 134: 310-314.
26. Bernbeck B, Mauz-Korholz C, Zotz RB, Gobel U. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr 2003; 215: 327-331.
27. Chao YC, Wang SJ, Chu HC, Chang WK, Hsieh TY. Investigation of alcohol metabolizing enzyme genes in Chinese alcoholics with avascular necrosis of hip joint, pancreatitis and cirrhosis of the liver. Alcohol Alcohol 2003;38: 431-436.
28. Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 1998; 59: 267-272.
29. Kutlar A, Kutlar F, Turker I, Tural C. The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin 2001; 25: 213-217.
30. Adekile A, Haider MZ, Marouf R, Adekile AD. HLA-DRB1 alleles in Hb SS patients with avascular necrosis of the femoral head. Am J Hematol 2005; 79: 8-10.
31. Baldwin C, Nolan VG, Wyszynski DF, Ma QL, Sebastiani P, Embury SH, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005; 106(1): 372-375.
32. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37: 435-440.
33. Glueck CJ, Glueck HI, Greenfield D, Freiberg R, Kahn A, Hamer T, et al. Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediatr Res 1994; 35: 383-388.
34. Glueck CJ, Brandt G, Gruppo R, Crawford A, Roy D, Tracy T, et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop Relat Res 1997; 338: 139-152.
35. Arruda VR, Belangero WD, Ozelo MC, Oliveira GB, Pagnano RG, Volpon JB, et al. Inherited risk factors for thrombophilia among children with Legg-Calve-Perthes disease. J Pediatr Orthop 1999; 19: 84-87.
36. Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, et al. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am 2004; 86-A: 2642-2647.
37. Hayek S, Kenet G, Lubetsky A, Rosenberg N, Gitel S, Wientroub S. Does thrombophilia play an aetiological role in Legg-Calve-Perthes disease? J Bone Joint Surg Br 1999; 81: 686-690.
38. Sirvent N, Fisher F, el Hayek T, Appert A, Giudicelli H, Griffet J. Absence of congenital prethrombotic disorders in children with Legg-Perthes disease. J Pediatr Orthop B 2000; 9: 24-27.
39. Schmitz A, Pfortner J, Protzel A, Harbrecht U. [Incidence of thrombophilic factor V Leiden and prothrombin G20210A mutation in Perthes disease-a pilot study]. Z Orthop Ihre Grenzgeb 2001; 139: 143-146.
40. Hresko MT, McDougall PA, Gorlin JB, Vamvakas EC, Kasser JR, Neufeld EJ. Prospective reevaluation of the association between thrombotic diathesis and Legg-Perthes disease. J Bone Joint Surg Am 2002; 84-A: 1613-1618.
41. Szepesi K, Posan E, Harsfalvi J, Ajzner E, Szucs G, Gaspar L, et al. The most severe forms of Perthes' disease associated with the homozygous Factor V Leiden mutation. J Bone Joint Surg Br 2004; 86: 426-429.
42. Lopez-Franco M, Gonzalez-Moran G, De Lucas JC Jr, Llamas P, de Velasco JF, Vivancos JC, et al. Legg-Perthes disease and heritable thrombophilia. J Pediatr Orthop 2005; 25: 456-459.
43. Dilley A, Hooper WC, Austin H, Jamil M, Miller C, Stokes M, et al. The beta fibrinogen gene G-455-A polymorphism is a risk factor for Legg-Perthes disease. J Thromb Haemost. 2003; 1: 2317-2321.
44. Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22: 3930-3936.